The most striking feature of herpes simplex virus (HSV) is its capability to establish latency after primary infection. HSV thereby becomes able to persist unperceived in the host in order to periodically reactivate and cause outbreaks of HSV infection during the whole lifetime. HSV type-1 (HSV-1) seroprevalence varies considerably, but increases with age and affects approximately 88% of individuals by the age of 40 years [1, 2] . Primary HSV-1 infection is usually mild or occurs subclinically, and in most cases occurs in early childhood. The reactivation of HSV-1 is triggered by stress, ultraviolet light, febrile illness, premenstrual tension, trauma or any kind of immunosuppression.
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Herpes labialis (HL) is the most common manifestation of recurrent oral HSV-1 infection. Between 20% and 40% of the population are estimated to have recurrent orolabial HSV-1 infections [3] . The effect of recurrent HL (RHL) in patients varies considerably: for some, it is an infrequent minor nuisance, but for others it is a frequent and invalidating condition. The number of outbreaks varies widely, ranging from rare episodes to monthly or even more frequent recurrences. The biological basis for the difference between infected individuals who do and those who do not suffer recurrences has long been a subject of clinical and laboratory investigation, including studies of genetic markers [1] , epidermal cell susceptibility [4] , relative potency of different HSV-1 strains [5, 6] and multiple assays of immunological function [1, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
The first line of defence against viral infections is mediated by interferons (IFNs). Type-I IFNs, also called IFN-α/β, combat viruses both directly, by inhibiting viral replication in the cells, and indirectly, by stimulating the innate and adaptive immune responses. [18, 19] , on the basis of its IFN-like antiviral activity and induction of typical IFN-inducible genes [20] [21] [22] . IFN-λ is expressed in response to most viruses and is able to inhibit the replication of HCV and HBV [22, 23] , human cytomegalovirus [24] , HSV type-2 (HSV-2) [25] , vesicular stomatitis virus [24] and HIV type-1 [26] . The antiviral activity of IFN-λ in vivo is limited, however, only to selected viruses [23, 25, 27] . IFN-λ exerts a significant portion of its antiviral activity in vivo via stimulation of the immune system rather than through induction of the antiviral state [25] ; hence, we still do not have a clear picture of the antiviral potential of IFN-λ in vivo or its mechanism of action.
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Interferon-λ in immunocompetent individuals
The aim of this study was to investigate in vitro the HSV-1-stimulated production of IFN-α, IFN-γ and IFN-λ using peripheral blood mononuclear cells (PBMCs) from patients with a history of RHL, HSV-1 -positive individuals without a history of HL and HSV-1 -seronegative individuals. The results of this study might help to elucidate the pathogenesis of recurrent HSV-1 infection in the immuno competent host.
Methods
Participants
Healthy immunocompetent individuals (≥18 years of age), with or without a history of RHL, were enrolled. They were recruited from among the outpatients of the Clinic of Infectious Diseases, Policlinico Tor Vergata (Rome, Italy) and as healthy volunteers from the Department of Experimental Medicine, University of Rome Tor Vergata (Rome, Italy), between July 2007 and December 2008. All individuals who gave voluntary informed consent to be included in the study were interviewed by medically trained investigators using a questionnaire, and agreed to undergo a blood test. The study was reviewed and obtained institutional review board approval from the Ethical Committee of the University of Rome Tor Vergata.
Data and sample collection
A standardized questionnaire was used (FP et al., data not shown). Briefly, participants in the study were asked a series of questions aimed at obtaining demographic data (name, age, sex and race/ethnicity) and the following information: medical history (diabetes or other underlying diseases) and HSV-1 history (memory of the first episode, number of recurrences per year, localization, dimensions and duration of the lesions, presence of a prodrome, intensity of pain, presence of neuralgia or other associated symptoms, and antiviral treatments).
Participants were excluded from the study if they were infected with HIV, had been diagnosed with cancer, and/or were undergoing treatment with immunosuppressive drugs, such as steroids or chemotherapy, in the 3 months preceding the blood test. Exclusion criteria also included: the systemic or topical use of antiviral drugs in the 3 weeks preceding blood sampling; the presence of documented HL complications involving the central nervous system, eye, and visceral and/ or cutaneous dissemination; the presence of concomitant diseases with a possible effect on the results of the study; and seropositivity to HSV-2. All data obtained from the interviews were recorded in database files.
Blood sampling (approximately 25 ml of entire blood were taken from each donor for the isolation of the PBMCs to be used for the experiments) was performed after an overnight fast. A fraction of plasma from each donor was stored at -20°C for the assessment of the HSV-1 and HSV-2 serological status. Biological material, stored anonymously and equipped with dual code, was kept at the Microbiology Laboratory, Department of Experimental Medicine, University of Rome Tor Vergata, until the end of the study.
Isolation and stimulation of PBMCs
PBMCs were obtained from heparinized blood (25 ml) using Ficoll-Hypaque (Cedarlane ® , Burlington, ON, Canada) gradient centrifugation, according to the standard technique. The viability of isolated PBMCs was >95% as revealed by trypan blue staining. PBMCs were cultivated at 37°C in a 5% CO 2 atmosphere in RPMI 1640 medium (Gibco-Invitrogen Co., Paisley, UK) containing 10% heat-inactivated (56°C, 60 min) fetal calf serum supplemented with 50 µg/ml glutamine, 200 U/ml penicillin and 90 U/ml streptomycin.
Freshly isolated PBMCs were plated in duplicate at a density of 2×10 6 cells/ml/well in 24-well flat bottom plates (Falcon, Oxnard, NY, USA). PBMCs were left unstimulated or stimulated immediately after isolation, with intact HSV-1 strain F1 (a kind gift from MG Santoro, Department of Biology, University of Rome Tor Vergata) at a multiplicity of infection of 1 plaqueforming unit/cell. The virus was produced and titrated as described previously [28] . The PBMC supernatants were harvested 24 and 48 h after viral stimulation and immediately stored at -20°C.
Determination of IFN production
PBMC supernatants were assayed for IFN-α, IFN-γ and IFN-λ production using commercially available ELISA kits (PBL Biomedical Laboratories and R&D System, Milan, Italy) according to the manufacturer's instructions. The detection limits of the assays were <12.5 pg/ml for IFN-α, <8.0 pg/ml for IFN-γ and <10 pg/ml for IFN-λ. The standard curves ranged from 12.5 to 500 pg/ml for IFN-α, from 15.6 to 1,000 pg/ ml for IFN-γ and from 10 to 4,000 pg/ml for IFN-λ. In general, 100-200 µl of cell culture supernatants were analysed unless values above the linear range required further dilution.
Serological testing
Coded plasma from participants in the study were frozen at -20°C, and subsequently assayed for HSV-1 and HSV-2 antibodies by means of commercially available ELISA kits using purified HSV-1 and gG2 antigens, respectively (Radim SpA, Pomezia, Italy), according to the manufacturer's instructions.
Statistical analyses
Median values were used for descriptive analyses. The Wilcoxon signed-rank test was used for comparisons between groups. All the statistical calculations assumed a two-sided significance at P-values <0.05. The analyses were performed using SPSS version 10 (SPSS Inc., Chicago, IL, USA).
Results
Characteristics of the study participants
A total of 40 individuals participated in the study, of whom 24 had a history of RHL, 12 were without a history of RHL but had serological evidence of HSV-1 infection, and 4 were HSV-1-seronegative controls. All participants were White Caucasian Italians.
The three groups were comparable with regards to standard demographic characteristics. RHL patients had a median age of 29 years (range 23-52), participants without RHL were median 34.5 years (range 23-48) and the HSV-1-seronegative controls were median 33 years (range [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . Among the RHL patients, 16 (67%) were female and 8 (33%) were male; very similar percentages were found in the group of patients without RHL, that is, 8 (66.7%) female and 4 (33.3%) male, whereas among HSV-1-seronegative controls, male and female participants were equally distributed.
None of the RHL patients presented active lesions at the time of blood sampling, or in the previous 3 weeks. Among the RHL patients, 9 (37.5%) recalled the first episode of HL occurring at 12-15 years of age, and 15 (62.5%) at approximately 20 years of age. No seasonal predilection for RHL was identified among them. The interviews revealed the occurrence of a stressful event usually preceding the onset of HL in 11 (45.8%) out of the 24 patients. The number of episodes of HL per year was >4 (range 5-10) in 14 (58.3%) patients and ≤4 (range 2-4) in the remaining 10 (41.6%). Most of the lesions developed on the upper and/or lower lips, whereas nose, cheeks, chin, gingivae and/or anterior palate were less frequently involved. No ocular lesion was reported by RHL patients. The onset of the lesions was preceded by mild pain, itching and/or burning in 18 (75%) out of the 24 patients. The size of the lesions varied from ≤1 to 3-4 cm. The duration of the lesions up to complete resolution ranged from 7 to 10 days in 7 (29%) patients and was <7 days in the remaining 17 (71%). The presence of neuralgia or paresthesias, associated with the onset and/or development of the lesions, was reported by 5 out of the 24 patients with RHL. Three RHL patients had never taken any medication, 7 had used aspecific therapies (alcohol, anesthetics or anti-inflammatory drugs for symptom relief) and 14 had used specific antiviral therapy (oral or topical treatment with acyclovir).
Production of IFNs
HSV-1-specific IFN-α, IFN-γ and IFN-λ production, as measured in the supernatants of cultured PBMCs from HSV-1-seropositive patients with or without a natural history of RHL, and from the HSV-1 seronegative controls, is shown in Table 1 and Figure 1 ). Briefly, 24 h after HSV-1 stimulation, PBMCs from patients with a history of RHL produced significantly lower levels of IFN-λ and marginally lower levels of IFN-α and IFN-γ than those from the history-negative HSV-1-seropositive controls. These differences remained at 48 h after HSV-1 stimulation, with the exception of IFN-γ, for which levels at this time point were found to be even higher than those in cell supernatants of PBMCs from the history-negative HSV-1-seropositive controls (Table 1) . Following in vitro HSV-1 stimulation, PBMCs from the HSV-1-seronegative participants showed undetectable IFN-γ production, but IFN-α and -λ levels similar to those of the RHL patients (P=0.068 for IFN-α and P=0.458 for IFN-λ). Finally, among the 24 RHL patients, the 10 individuals who referred more frequent and severe HL recurrences indicated a significant trend towards lower levels of IFN-λ production (median [range] 39 pg/ml versus 100 pg/ml 
Discussion
HL is usually considered of little consequence, although it can cause considerable discomfort, even in patients affected by minor manifestations. Primary and recurrent infections represent a significant reservoir of virus with the potential for transmission to oral and genital sites during periods of intimate contact with other individuals. The precise relationship between symptomatic and asymptomatic shedding and transmission is unclear, but it is known that virus titres during asymptomatic outbreaks are much lower than in the presence of clinically manifest disease [29] .
Given the increased prevalence of HSV-1 infection in the general population, what remains unclear is how susceptibility to HSV recurrences originate only in a small proportion of infected people. Many reports indicate an altered immune response as a correlate of HSV-1 recurrent infection [9] [10] [11] [12] [13] [14] [15] [16] [17] . A T-helper 1 (Th1)-like cytokine response (IFN-γ and IL-2 production) has been associated with resistance to naturally occurring episodes of HL and a T-helper 2 (Th2) profile with a higher susceptibility to recurrent disease [17] . The major role of the cell-mediated immune response to HSV-1 in the control and clearance of recurrent infection in oral or genital herpes has been shown [30] . It has also been shown that low levels of antibodydependent cellular cytotoxicity-mediating immunoglobulin G1 and G3 antibodies, partly dependent of allotypes, might predispose to HSV-2 recurrent genital infection [31] .
A correlation between defective antiviral immunity and disease severity has been proposed for two other clinical manifestations of HSV infection, that is, acute retinal necrosis and encephalitis [32, 33] . Numerical and functional deficits in plasmacytoid dendritic cell (PDC)-mediated innate immune response contribute to an impaired control of latent herpesvirus infections and subsequent development of acute retinal necrosis [32] . PDCs are the major producers of type-I IFNs in the blood [34, 35] and are important for the recognition and control of viral and bacterial infections [36] [37] [38] . HSV-1 encephalitis has been linked with an autosomal recessive UNC-93B deficiency resulting in impaired cellular IFN antiviral response in two otherwise healthy children [33] . UNC-93B is an endoplasmic reticulum protein involved in the activation of selected types of Toll-like receptors (TLRs), whose role in immunity has recently been identified [33, 39] . It is known that TLR-3, TLR-4, TLR-7, TLR-8 and TLR-9 can trigger IFN-α, IFN-β and IFN-λ [40] .
Here, we show that PBMCs from patients with a history of RHL respond to HSV-1 stimulation with a significantly reduced production of IFN-λ and only marginally lower levels of IFN-α and IFN-γ than the history-negative HSV-1-seropositive controls. This defective IFN antiviral response is different from that described in children with HSV-1 encephalitis [33] . Considering the different degree of severity between herpes encephalitis and HL, one could speculate that IFN-α is more crucial than IFN-λ or IFN-γ in antiviral immunity; however, this is probably only partially true. Recent research highlight the existence of pathogendependent, as well as tissue-dependent, pathways of antiviral response [41, 42] .
The existence of two types of antiviral IFNs, using different receptors [18, 19] , and the multitude of IFN-α/β and IFN-λ molecules, raises questions about the redundancy of the different pathways of IFN induction in viral diseases, but might also reflect a need to protect the body against a large array of viruses, in many tissues and at all ages. When considering the producer and the responder cell types, important differences between IFN-α and IFN-λ can be found. Virtually all cell types are capable of producing type-I IFNs in response to viral infections, with the amount of IFN being virus and cell-type dependent [43] and with PDCs being the most potent producers of type-I IFN [44] . Human monocytes represent a competitive source of IFN-α in peripheral blood [45] . INF-λ is produced by a number of cell types, although the pattern of expression has not been completely elucidated. One report shows that IFN-λ is produced by PDC to a greater extent than by monocyte-derived dendritic cells after influenza A virus infection [46] , but this needs to be confirmed for other virus infections. In contrast to IFN-α, which stimulate nearly all nucleated cells, only a few cell types are responsive to IFN-λ, including PDCs and epithelial cells [18] [19] [20] 47, 48] . These data suggest that IFN-λ is an antiviral cytokine targeting only a subset of cell types, many of which are located at important portals of entry into the body that constitute primary sites of virus replication [47] . Consistently, IFN-λ is essential for TLR-activated antiviral protection in a model of mucosal infection with HSV-2, and this antiviral activity is largely mediated by the induction of an antiviral state in epithelial cells [47] . Modulation of the Th1/Th2 response by IFN-λ has been also reported [49, 50] .
Our study has some potential limitations, among which are the small number of patients examined, the wide variation in the cytokine results and the possibility of recall bias during the interviews. It is conceivable that retrospective patient memory of recurrence rate is not as accurate as prospective studies. In addition, although none of the RHL patients presented active lesions at the time of blood sampling or in the previous 3 weeks, the possibility of asymptomatic viral shedding and/or of abortive lesions cannot be excluded. In this regard, a persistent expression of IFN-γ during healing and at 2-4 weeks post-healing in recurrent HSV-2 infection has been reported [51, 52] and this could explain, at least in part, the wide variations in IFN-γ levels observed in our patients.
Notwithstanding these limitations, some interesting hypotheses have emerged from this study for future testing. First, we hypothesize that systemic as well as mucosal production of IFN-λ might be an important factor in down-regulating the frequency of naturally occurring HL in the history-negative HSV-1-seropositive individuals. Second, our data suggest that the test we performed on freshly isolated PBMCs might be used in clinical practice to predict individual patterns of antiviral response addressing more successful therapeutic or prophylactic intervention. Further and larger prospective cohort studies are needed to address these questions.
